A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
Eligible age
18+ yrs
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Where it's recruiting
Phoenix
Los Angeles · Redlands · Sherman Oaks · Valley Village
Hallandale · Orlando
Methuen · Watertown
Cherry Hill
Jamaica · New York · The Bronx
Oklahoma City
Portland
Philadelphia
Memphis
Austin · Houston
Fairfax
Source: ClinicalTrials.gov · NCT07767903 · last updated 2026-11-12